SCHEMBL16635290

SCHEMBL16635290

COC(=O)C1CC(O)(CO[Si](C)(C)C(C)(C)C)CN1C(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 3/20 0.40
HDAC8 Q9BY41 1/20 0.35
PTPN1 P18031 1/20 0.35
NR1H2 P55055 2/20 0.33
NR1H3 Q13133 1/20 0.33
EPHX2 P34913 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.31
USP2 O75604 1/20 0.31
PEPD P12955 1/20 0.31
CCR2 P41597 1/20 0.31
ALDH1A1 P00352 1/20 0.30
PDE4B Q07343 1/20 0.30
MAPK1 P28482 1/20 0.30
FKBP1A P62942 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20113066 1.00 IMPDH2 (0.40) IMPDH2HDAC8PTPN1NR1H2NR1H3
SCHEMBL16774503 0.86 IMPDH2 (0.39) IMPDH2HDAC8PTPN1NR1H2NR1H3
SCHEMBL16774639 0.86 IMPDH2 (0.39) IMPDH2HDAC8PTPN1NR1H2NR1H3
SCHEMBL20113067 0.85 IMPDH2 (0.38) IMPDH2HDAC8PTPN1NR1H2NR1H3
SCHEMBL16647818 0.84 IMPDH2 (0.39) IMPDH2HDAC8PTPN1NR1H2NR1H3
SCHEMBL16635559 0.84 IMPDH2 (0.39) IMPDH2HDAC8PTPN1NR1H2NR1H3
SCHEMBL2380326 0.84 IMPDH2 (0.39) IMPDH2HDAC8PTPN1NR1H2NR1H3
SCHEMBL2380328 0.84 IMPDH2 (0.39) IMPDH2HDAC8PTPN1NR1H2NR1H3
SCHEMBL12479707 0.83 FKBP1A (0.42) FKBP1A
SCHEMBL12480970 0.83 FKBP1A (0.42) FKBP1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11236046-B2 Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators GENENTECH, INC. (US) 2022-02-01 US disclosed
US-20200048197-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS GENENTECH, INC. (US) 2020-02-13 US disclosed
EP-3055302-B1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS HOFFMANN LA ROCHE (CH) 2018-12-26 EP disclosed
US-20180282272-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS GENENTECH, INC. (US) 2018-10-04 US disclosed
EP-3055302-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS F. Hoffmann-La Roche AG (CH) 2016-08-17 EP disclosed
US-20160221945-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS GENENTECH, INC. (US) 2016-08-04 US disclosed
WO-2015052264-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221945-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS TRPA1, TRPV1, TRPV2 IMPDH2 3317/4885HDAC8 1732/4885PTPN1 2070/4885
US-20180282272-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS TRPA1, TRPV1, TRPV2 IMPDH2 3317/4885HDAC8 1732/4885PTPN1 2070/4885
US-20200048197-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS TRPA1, TRPV1, TRPV2 IMPDH2 3317/4885HDAC8 1732/4885PTPN1 2070/4885
US-11236046-B2 Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators TRPA1, TRPV1, TRPV2 IMPDH2 3317/4885HDAC8 1732/4885PTPN1 2070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.